Skip to main content
SpringerLink
Log in

Transforming Growth Factor-λ1 as a Novel Marker of Response to Therapy for Renal Cell Carcinoma

  • Protocol
Renal Cancer

Part of the book series: Methods in Molecular Medicine ((MIMM,volume 53))

  • 398 Accesses

Abstract

Renal cell carcinoma is expected to account for 30,000 new cancer cases and 11,900 cancer deaths in the United States in 1999 (1). At the time of initial presentation, up to one-third of patients with renal cell carcinoma (RCC) have metastatic disease; furthermore, almost half of the patients resected for cure will relapse (2). Due to the poor results of cytotoxic chemotherapy in the management of metastatic RCC (3), physicians have explored the use of new therapies including immunotherapy and gene therapy. Some of these therapies are discussed in other chapters of this textbook. The use of these new therapies allows for the identification and utilization of new tumor markers that may allow investigators to identify patients at risk for advanced disease as well as establish new definitions of tumor response.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P.A. (1999) Cancer statistics, 1999. CA Cancer J. Clin.49, 8–31.

    Article  CAS  Google Scholar 

  2. Figlin, R. A. (1999) Renal cell carcinoma: management of advanced disease. J. Urol.161, 381–387.

    Article  CAS  Google Scholar 

  3. Yagoda, A., Abi-Rached, B., and Petrylak, D. (1995) Chemotherapy for advanced renal cell carcinoma, 1983-1993. Semin. Oncol.22, 42–60.

    CAS  PubMed  Google Scholar 

  4. Nicol, D., Hii, S.-I., Walsh, M., Teh, B., Thompson, L., Kennett, C., and Gotley, D. (1997) Vascular endothelial growth factor expression is increased in renal cell carcinoma. J. Urol.157, 1482–1486.

    Article  CAS  Google Scholar 

  5. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Dvorak, H. F., and Senger, D. R. (1993) Increased expression of vascular permeability growth factor (vascular endothelial growth factor) and its receptors in the kidney and bladder carcinomas. Am. J. Pathol.143, 1255–1262.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Takahashi, A., Sasaki, H., Kim, S. J., Tobisu, K., Kakizoe, T., Tsukamoto, T., Kumamoto, Y., Sugimura, T., and Terada, M. (1994) Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res.54, 4233–4237.

    CAS  PubMed  Google Scholar 

  7. Dyrix, L. Y., Vermeulen, P. B., Pawinski, A., Prove, A., Benoy, I., De Pooter, C., Martin, M., and Van Oosterom, A. T. (1997) Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br. J. Cancer76, 238–243.

    Article  Google Scholar 

  8. Vermeulen, P. B., Dirix, L. Y., Martin, M., Lemmens, J., and Van Oosteram, A. T. (1997) Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b. J. Natl. Cancer Inst.89, 1316–1317.

    Article  CAS  Google Scholar 

  9. O′Byrne, K. J., Propper, D., Braybrooke, J., Crew, J., Mitchell, K., Woodhull, J., Dobbs, N., Ganesan, T. S., Talbot, D. C., and Harris, A. L. (1997) Razoxane: a phase II trial in renal cell cancer evaluating anti-angiogenic activity. Proc. Annu. Meeting Am. Soc. Clin. Oncol.16, A1160.

    Google Scholar 

  10. Baccala, A. A., Zhong, H., Clift, S. M., Nelson, W. G., Marshall, F. F., Passe, T. J., Gambill, N. B., and Simons, J. W. (1998) Serum vascular endothelial growth factor is a candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell cancer. Urology51, 327–332.

    Article  CAS  Google Scholar 

  11. Wahl, S. M., McCartney-Francis, N., and Mergenhagen, S. E. (1989) Inflammatory and immunomodulatory roles of TGF-β. Immunol. Today10, 258–261.

    Article  CAS  Google Scholar 

  12. Rifkin, D. B., Kojima, S., Abe, M., and Harpel, J. G. (1993) TGF-β: structure, function, and formation. Thromb. Haemost.70, 177–179.

    Article  CAS  Google Scholar 

  13. Assoian, R. K., Komoriyama, A., Meyers, C. A., Miller, D. M., and Sporn, M. B. (1983) Transforming growth factor-β in human platelets. J. Biol. Chem.258, 7155–7160.

    CAS  PubMed  Google Scholar 

  14. Shipley, E. D., Pittelkow, M. R., Wille, J. J. Jr., Scott, R. E., and Moses, H. L. (1986) Reversible inhibition of normal human prokeratinocyte by type β transforming growth factor-growth inhibitor in serum-free medium. Cancer Res.46, 2068–2071.

    CAS  PubMed  Google Scholar 

  15. Yang, E. Y. and Moses, H. L. (1990) Transforming growth factor-β 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J. Cell Biol.111, 731–741.

    Article  CAS  Google Scholar 

  16. Rook, A. H., Kehrl, J. H., Wakefield, L. M., Roberts, A. B., Sporn, M. B., Burlington, D. B., Lane, H. C., and Fauci, A. S. (1986) Effects of transforming growth factor-β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol.136, 3916–3920.

    CAS  PubMed  Google Scholar 

  17. Tada, T., Ohzeki, S., Utsumi, K., Takiuchi, H., Muramatsu, M., Li, X.-F., Shimizu, J., Fujiwara, H., and Hamaoka, T. (1991) Transforming growth factor-β induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J. Immunol.146, 1077–1082.

    CAS  PubMed  Google Scholar 

  18. Wahl, S. M. (1992) Transforming growth factor beta (TGF-β) in inflammation: a cause and a cure. J. Clin. Immunol.12, 61–74.

    Article  CAS  Google Scholar 

  19. Wahl, S. M. (1994) Transforming growth factor β: the good, the bad, and the ugly. J. Exp. Med.180, 1587–1590.

    Article  CAS  Google Scholar 

  20. Kong, F.-M., Anscher, M. S., Murase, T., Abbott, B. D., Inglehart, D., and Jirtle, R. L. (1995) Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann. Surg.222, 155–162.

    Article  CAS  Google Scholar 

  21. Tsushima, H., Kawata, S., Tamura, S., Ito, N., Shirai, Y., Kiso, S., Imai, Y., Shimomukai, H., Nomura, Y., Matsuda, Y., and Matsuzawa, Y. (1996) High levels of transforming growth factor β1 in patients with colorectal cancer: association with disease progression. Gastroenterology110, 375–382.

    Article  CAS  Google Scholar 

  22. Shirai, Y., Kawata, S., Ito, N., Tamura, S., Takaishi, K., Kiso, S., Tsushima, H., and Matsuzawa, Y. (1992) Elevated levels of plasma transforming growth factor-P in patients with hepatocellular carcinoma. Jpn. J. Cancer Res.83, 676–679.

    Article  CAS  Google Scholar 

  23. Kong, F.-M., Washington, M. K., Jirtle, R. L., and Anscher, M. S. (1996) Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer16, 47–59.

    Article  CAS  Google Scholar 

  24. Ivanovic, V., Melman, A., Davis-Joseph, B., Valcic, M., and Geliebter, J. (1995) Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nat. Med.1, 282–284.

    Article  CAS  Google Scholar 

  25. Kaheki, Y., Oka, H., Mitsumori, K., Itoh, N., Ogawa, O., and Yoshida, O. (1996) Elevation of serum transforming growth factor-β1 level in patients with metastatic prostate cancer. Urol. Oncol.2, 131–135.

    Article  Google Scholar 

  26. Adler, H. L., McCurdy, M. A., Kattan, M. W., Timme, T. L., Scardino, P. T., amd Thompson, T. C. (1998) Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J. Urol.161, 182–187.

    Article  Google Scholar 

  27. Ramp, U., Jaquet, K., Reinecke, P., Scardt, C., Friebe, U., Nitsch, T., Marx, N., Gabbert, H. E., and Gerharz, C.-D. (1997) Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type. J. Urol.157, 2345–2350.

    Article  CAS  Google Scholar 

  28. Knoefel, B., Nuske, K., Steiner, T., Junker, K., Kosmehl, H., Rebstock, K., Reinhold, D., and Junker, U. (1997) Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-β1 in primary cultures and modulate T lymphocyte blast transformation. J. Interferon Cytokine Res.17, 95–102.

    Article  CAS  Google Scholar 

  29. Junker, U., Knoefel, B., Nuske, K., Rebstock, K., Steiner, T., Wunderlich, H., Junker, K., and Reinhold, D. (1996) Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma. Cytokine8, 794–798.

    Article  CAS  Google Scholar 

  30. Wunderlich, H., Steiner, T., Kosmehl, H., Junker, U., Reinhold, D., Reichelt, O., Zermann, D. H., and Schubert, J. (1998). Increased transforming growth factor β1 plasma level in patients with renal cell carcinoma: a tumor-specific marker? Urol. Int.60, 205–207.

    Article  CAS  Google Scholar 

  31. Wunderlich, H., Steiner, T., Junker, U., Knoefel, B., Schlichter, A., and Schubert, J. (1997) Serum transforming growth factor-β1 in patients with renal cell carcinoma. J. Urol.157, 1602–1603.

    Article  CAS  Google Scholar 

  32. Puolakkainen, P., Twardzik, D., Ranchalis, J., Moroni, M., Mandeli, J., and Paciucci, P. A. (1995) Increase of plasma transforming growth factor beta (TGFβ) during immunotherapy with IL-2. Cancer Invest.13, 583–589.

    Article  CAS  Google Scholar 

  33. Adler, H. L., Lee, H.-M., McCurdy, M. A., Herman, J. R., Timme, T. L., Scardino, P. T., and Thompson, T. C. (1998) Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in men with radiorecurrent prostate cancer leads to stimulation of the immune system and increases in circulating cytokines. Proc. 1st Annu. Meeting Am. Soc. Gene Therapy1, A442.

    Google Scholar 

  34. Marie, C., Cavaillon, J.-M., and Losser, M.-R. (1996) Elevated levels of circulating transforming growth factor-β1 in patients with the sepsis syndrome. Ann. Int. Med.125, 520–521.

    Article  CAS  Google Scholar 

  35. Yang, E. Y. and Moses, H. L. (1990) Transforming growth factor β1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J. Cell Biol.111, 731–741.

    Article  CAS  Google Scholar 

  36. Miyazono, K., Hellman, U., Wernstedt, C., and Heldin, C.-H. (1988) Latent high molecular weight complex of transforming growth factor β 1: purification from human platelets and structural characterization. J. Biol. Chem.263, 6407–6415.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, SUNY Health Science Center at Stony Brook, Stony Brook, NY, USA

    Howard L. Adler

Authors
  1. Howard L. Adler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Temple University School of Medicine, Philadelphia, PA

    Jack H. Mydlo MD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Humana Press Inc.

About this protocol

Cite this protocol

Adler, H.L. (2001). Transforming Growth Factor-λ1 as a Novel Marker of Response to Therapy for Renal Cell Carcinoma. In: Mydlo, J.H. (eds) Renal Cancer. Methods in Molecular Medicine, vol 53. Humana, Totowa, NJ. https://doi.org/10.1385/1-59259-144-2:377

Download citation

  • DOI: https://doi.org/10.1385/1-59259-144-2:377

  • Publisher Name: Humana, Totowa, NJ

  • Print ISBN: 978-0-89603-828-8

  • Online ISBN: 978-1-59259-144-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation